

**Vaxon-Biotech to Present Latest Clinical Data  
of its Vx-001 Cancer Vaccine  
at the AACR 97<sup>th</sup> Annual Meeting**

P  
R  
E  
S  
S  
  
R  
E  
L  
E  
A  
S  
E

**Evry-Genopole, France, Mars 14, 2006** – Vaxon-Biotech announces that most recent clinical data from the Vx-001 cancer vaccine trial will be presented at the AACR 97<sup>th</sup> Annual Meeting by Dr Kostas Kosmatopoulos, Chief Scientific Officer of Vaxon-Biotech. The meeting will take place in Washington DC, April 1-5, 2006.

About Vaxon-Biotech

Vaxon Biotech, founded in early 2004 and based in Evry Genopole - France, is a product-driven biopharmaceutical company focusing on the discovery and development of innovative vaccines for the treatment of cancer. The first two products under development, Vx-001 and Vx-006, are novel treatments for solid tumors. For more information, go to [www.vaxon-biotech.com](http://www.vaxon-biotech.com).

Contacts

Philippe Berthon, PhD  
CEO  
+33(0)160789210  
[pberthon@vaxon-biotech.com](mailto:pberthon@vaxon-biotech.com)